EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases

Valentina Bellani iD, Giorgio Alberto Croci, Cristina Bucelli, Carlo Alberto Maronese iD, Sara Alberti, Alessandra Iurlo, Daniele Cattaneo

The Journal of Dermatology · 2023

DOI: 10.1111/1346-8138.16836 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Valentina Bellani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Lymphomatoid Papulosis, Hypereosinophilic Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphomatoid papulosis (LyP) is a benign condition, listed among primary cutaneous CD30+ lymphoproliferative disorders. Its typical picture consists of relapsing–remitting papular lesions and it can be encountered in the course of a hematologic disease, at times representing its first manifestation. Hypereosinophilic syndromes are a heterogeneous group of disorders characterized by persistent peripheral blood hypereosinophilia that may lead to life‐threatening organ damage. Among eosinophilic disorders, the subtype identified as myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions has aroused particular interest due to its excellent response to tyrosine kinase inhibitors, including imatinib. Here, we described the case of two 33‐year‐old men presenting with LyP and myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement who achieved complete clinical and molecular remission of both conditions a few months after starting imatinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphomatoid PapulosisHypereosinophilic SyndromeMaleHumansImatinib MesylateReceptor, Platelet-Derived Growth Factor alphaNeoplasm Recurrence, LocalTranscription FactorsOncogene Proteins, Fusion

Stichwörter der Autor:innen

FIP1L1::PDGFRAhypereosinophiliaimatiniblymphomatoid papulosismyeloid neoplasm

Substanzen

Imatinib MesylateReceptor, Platelet-Derived Growth Factor alphaTranscription FactorsOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Division of Pathology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Dermatology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

ORCID-Profile: Valentina Bellani, Carlo Alberto Maronese

Zitieren

APA

Bellani, V., Croci, G. A., Bucelli, C., Maronese, C. A., Alberti, S., Iurlo, A., & Cattaneo, D. (2023). Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16836

Vancouver

Bellani V, Croci GA, Bucelli C, Maronese CA, Alberti S, Iurlo A, et al. Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16836

BibTeX
@article{Bellani2023,
  author = {Bellani, Valentina and Croci, Giorgio Alberto and Bucelli, Cristina and Maronese, Carlo Alberto and Alberti, Sara and Iurlo, Alessandra and Cattaneo, Daniele},
  title = {Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases},
  journal = {The Journal of Dermatology},
  year = {2023},
  doi = {10.1111/1346-8138.16836}
}
Kostenlos starten →